Current state and future directions of neurochemical biomarkers for Alzheimer's disease
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
In this comprehensive review, we summarize the current state-of-the-art of neurochemical biomarkers for Alzheimer's disease. Predominantly, these biomarkers comprise cerebrospinal fluid biomarkers directly related to the pathophysiology of this disorder (such as amyloid β protein, tau protein). We particularly pay attention to the innovations in this area that have been made in technological aspects during the past 5 years (e.g., multiplex analysis of biomarkers, proteomics), to the discovery of novel, potential biomarkers (e.g., amyloid β oligomers, isoprostanes), and to the extension of this research towards identification of biomarkers in plasma. Clin Chem Lab Med 2007;45:1421–34.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Cruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512
Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., & Van Hoesen, G. W. (1991) · Cerebral Cortex · doi:10.1093/cercor/1.1.103 · Cited by 1,380
Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.
(1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.416 · Cited by 1,331
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Augustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573
Rosengren, L. E., Karlsson, J., Karlsson, J., Persson, L. I., & Wikkelsø, C. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67052013.x · Cited by 499
Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study
van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70501-4 · Cited by 458
Galasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Hampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434
Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk
Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434
Increased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Pratico, D., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1777 · Cited by 405
Hampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Dodel, R., Du, Y., Farlow, M., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001473 · Cited by 287
Fluctuations of CSF amyloid-β levels: Implications for a diagnostic and therapeutic biomarker
Bateman, R. J., Wen, G., Morris, J. C., & Holtzman, D. M. (2007) · Neurology · doi:10.1212/01.wnl.0000256043.50901.e3 · Cited by 260
Itoh, N., Arai, H., Urakami, K., Ishiguro, K., Ohno, H., Hampel, H., Buerger, K., Wiltfang, J., Otto, M., Kretzschmar, H., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1054 · Cited by 256
Riemenschneider, M., Wagenpfeil, S., Vanderstichele, H., Otto, M., Wiltfang, J., Kretzschmar, H., Vanmechelen, E., Förstl, H., & Kurz, A. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001220 · Cited by 238
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease
Grossman, M., Farmer, J., Leight, S., Work, M., Moore, P., Van Deerlin, V., Pratico, D., Clark, C. M., Coslett, H. B., Chatterjee, A., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20477 · Cited by 228
Neurofilament protein in cerebrospinal fluid: A marker of white matter changes
Sjögren, M., Blomberg, M., Jonsson, M., Wahlund, L. ‐., Edman, Å., Lind, K., Rosengren, L., Blennow, K., & Wallin, A. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1242 · Cited by 209
Longitudinal stability of CSF biomarkers in Alzheimer's disease
Blennow, K., Zetterberg, H., Minthon, L., Lannfelt, L., Strid, S., Annas, P., Basun, H., & Andreasen, N. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.03.064 · Cited by 193
Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
Sjögren, M., Rosengren, L., Minthon, L., Davidsson, P., Blennow, K., & Wallin, A. (2000) · Neurology · doi:10.1212/wnl.54.10.1960 · Cited by 181
Parnetti, L., Lanari, A., Amici, S., Gallai, V., Vanmechelen, E., & Hulstaert, F. (2001) · Neurological Sciences · doi:10.1007/s100720170055 · Cited by 141
Amyloid‐β oligomers are inefficiently measured by enzyme‐linked immunosorbent assay
Stenh, C., Englund, H., Lord, A., Johansson, A., Almeida, C. G., Gellerfors, P., Greengard, P., Gouras, G. K., Lannfelt, L., & Nilsson, L. N. G. (2005) · Annals of Neurology · doi:10.1002/ana.20524 · Cited by 99
de Jong, D., Jansen, R. W. M. M., Kremer, B. P. H., & Verbeek, M. M. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.7.755 · Cited by 98
Self-citationEnhanced brain levels of 8,12- iso -iPF 2α -VI differentiate AD from frontotemporal dementia
Yao, Y., Zhukareva, V., Sung, S., Clark, C. M., Rokach, J., Lee, V. M.-Y., Trojanowski, J. Q., & Praticò, D. (2003) · Neurology · doi:10.1212/01.wnl.0000070185.02546.5d · Cited by 86
Soluble adhesion molecules and angiotensin-converting enzyme in dementia
Nielsen, H. M., Londos, E., Minthon, L., & Janciauskiene, S. M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.11.011 · Cited by 80
Buerger, K., Otto, M., Teipel, S. J., Zinkowski, R., Blennow, K., DeBernardis, J., Kerkman, D., Schröder, J., Schönknecht, P., Cepek, L., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.12.003 · Cited by 70
Rentzos, M., Zoga, M., Paraskevas, G. P., Kapaki, E., Rombos, A., Nikolaou, C., Tsoutsou, A., & Vassilopoulos, D. (2006) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988706286226 · Cited by 65
Cited by
Rissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119
The overlap between vascular disease and Alzheimer’s disease - lessons from pathology
Attems, J., & Jellinger, K. A. (2014) · BMC Medicine · doi:10.1186/s12916-014-0206-2 · Cited by 739
“In addition to the presence of superficial siderosis, cerebral microbleeds, cortical microinfarcts, and hypointensities in MRI images [106-109], the use of Pittsburgh Compound-B (PiB)positron emission tomography (PET) is useful in detecting CAA intra vitam [110,111], and a significant decrease of both Aβ-40 and Aβ-42…”
BackgroundCerebral amyloid angiopathy in the elderly
Viswanathan, A., & Greenberg, S. M. (2011) · Annals of Neurology · doi:10.1002/ana.22516 · Cited by 643
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 631
Charidimou, A., Gang, Q., & Werring, D. J. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301308 · Cited by 611
Metadata
- Authors
- de Jong, D., Kremer, B. P. H., Olde Rikkert, M. G. M., & Verbeek, M. M.
- Venue
- Clinical Chemical Laboratory Medicine
- Publisher
- Walter de Gruyter GmbH
- Published
- 2007-01-01
- Volume
- 45
- Issue
- 11
- Pages
- 1421-34
- ISSN
- 1434-6621 (ISSN-L)
- 1437-4331
- OpenAlex
- W2130794043
- Cited by
- 84
- References
- 37
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.